The Effect and Safety of Different Doses of Atropine on Myopic Progression of Highly Myopic Children: Multi-centered Randomized Clinical Trial

Inclusion Criteria:

• At least one eye with cycloplegic optometric spherical equivalent of -5.00 to -10.00D and best corrected distant visual acuity of at least 0.5 and near visualacuity of at least 1.0, Titmus Stereo acuity ≤ 80 seconds, Vision with externaloccultation of ≤ 10 prismatic diopters , vision with internal occultation of ≤ 6-8prismatic diopters, and astigmatism equal to or less than -2.50D;

• Myopia progression greater than 0.5D in the past year;

• Possess normal cognitive and verbal communication abilities to actively cooperatewith the prescribed treatment;

• Written informed consent from the guardian and the child.

Exclusion Criteria:

• Diseases of the study eye: keratitis, cone cornea, congenital cataract, glaucoma,fundus diseases; combined with inflammation of the anterior or posterior segment ofthe eye, such as acute conjunctivitis, iridocyclitis;

• Systemic diseases affecting the use of drugs: albinism, epilepsy, severepsychoneurological disorders, congenital heart disease, cardiac arrhythmias;

• Atropine allergy;

• Very low birth weight less than 1500 g;

• Previous treatment with anticholinergics including atropine within the previous 1year, or use of OK lenses, multifocal soft lenses within 3 months;

• Other conditions judged by the investigator to be unsuitable for participation inthe trial.